1087 results about "Protein expression" patented technology

The invention provides an UTR (Untranslated Region) element H2202 P1-G as well as a construction method and application thereof, and relates to the technical field of mRNA (messenger ribonucleic acid). According to the present invention, the ribosome load prediction and the secondary structure optimization are performed on the natural 5 'UTR of the HIV TAT 202 gene through the BaidleHelix platform, and the obtained HTAT 202 P1 sequence avoids the inhibitory hairpin structure so as to significantly improve the luciferase expression quantity compared to the natural UTR; an ncRNA sequence without a secondary structure is introduced on the basis of the HTAT 202 P1, translation inhibition of a 5 'cap region is further relieved, and the protein expression quantity of the constructed H2202 P1-G mutant (the DNA sequence of the H2202 P1-G is as shown in SEQ NO 1, and the RNA sequence is as shown in SEQ NO 2) is further improved.

The invention provides a rapid quantitative analysis method for an outer vesicle proteome, and belongs to the technical field of quantitative analysis of the outer vesicle proteome. According to the rapid quantitative analysis method for the outer vesicle proteome, firstly, a high-quality outer vesicle sample is obtained through low-speed centrifugation, ultra-speed centrifugation and membrane filtration; and obtaining proteome data by utilizing two-dimensional electrophoresis and mass spectrometry. Then, a mathematical model equation set is constructed for preliminary analysis, a protein interaction network is optimized through an embedded game optimization index model, and feature extraction and quantitative analysis are conducted through a convolution parameter adaptive function and a residual network deep learning model; finally, a quantitative analysis result containing the protein expression level and the function importance is generated in combination with the multi-dimensional protein expression contribution index, and the technical problem that in the prior art, in the rapid quantitative analysis process of the outer vesicle proteome, the protein component complexity is high, and consequently the quantitative precision is low is solved.

The invention belongs to the technical field of environmental biology, and particularly relates to a prothioconazole methyltransferase gene proS38 and application thereof. The prothioconazole methyltransferase proS38 gene in the Sphingomonas sp.AJ-1 strain and the prothioconazole methyltransferase which is a protein expression substance thereof are found through analysis, screening, identification and verification, the prothioconazole methyltransferase proS38 gene and the prothioconazole methyltransferase which is a protein expression substance thereof are proved to have efficient and specific degradation catalysis capability on the existing pesticide prothioconazole which is used in a large amount, and a foundation is laid for biodegradation of prothioconazole.

The invention relates to a method for inhibiting in-vitro infection of a porcine epidemic diarrhea virus by using JPH203 and application. The JPH203 can be used for preparing an antiviral drug for inhibiting infection of the porcine epidemic diarrhea virus. JPH203 with the concentration of 5 [mu] M is added in the process that Vero cells are infected with PEDV, compared with a control group without JPH203, the virus infection condition, the protein expression quantity, the RNA content and the virus titer of the PEDV in a treatment group with JPH203 are all remarkably reduced, and it is indicated that JPH203 can be used for inhibiting in-vitro infection of the porcine epidemic diarrhea virus.

The present disclosure, in some aspects, relates to antisense oligonucleotides (ASO) for use in the prevention or treatment of a disease or a condition associated with low- density lipoprotein (LDL) in a subject. In some embodiments, the ASO effects site-directed adenosine-to-inosine (A-to-l) editing of a target adenosine in a target RNA sequence derived from a sequence of an endogenous low-density lipoprotein receptor (LDLR) gene such that: a) the modified LDLR protein has: (i) reduced binding to the inducible degrader of the LDLR protein (IDOL); (ii) increased stability; (iii) improved resistance to IDOL-mediated degradation; (iv) increased LDLR protein expression; and / or (v) increased activity or function to take up LDL; and / or b) editing of the 3'-untranslated region (UTR) of the target RNA leads to an increase in LDLR protein expression and / or stability.

The application provides an in-vitro cell-free protein synthesis system and kit containing exogenous magnesium ions and application thereof, including a D2P system (DNA-to-Protein system) and an mR2P system (mRNA-to-Protein system), and belongs to the technical field of protein synthesis. The in-vitro cell-free protein synthesis system containing exogenous magnesium ions adopts magnesium aspartate as a novel magnesium ion source, and especially in a eukaryotic cell-free system, compared with a traditional magnesium ion source, can significantly improve the protein synthesis efficiency and protein expression amount. A more efficient and higher-throughput in-vitro protein synthesis kit and a synthesis method of exogenous proteins are also provided, and the kit has the advantages of simplicity, convenience and low cost.

The present invention is directed to lipid nanoparticles using cationic cholesterol for topical delivery for nucleic acid delivery, and when administered locally, side effects caused by systemic drug delivery can be minimized and protein expression can be confined to the site of administration. In addition, the duration of protein expression at the site of administration can be increased, and thus the lipid nanoparticles can be useful in the technical field related to nucleic acid therapeutics.

The invention provides an engineered ketoreductase mutant, which comprises a polypeptide sequence, a gene sequence, a recombinant expression vector containing the gene, an engineering strain, a protein expression method of the engineering strain, and a reaction process for selectively synthesizing (R)-5, 7-difluorochroman-4-ol by using the engineered ketoreductase mutant.

The invention discloses a risk assessment method, system and equipment for idiopathic pulmonary arterial hypertension, and belongs to the field of pulmonary arterial hypertension. According to the method, SNP data containing genotypes and effect values, protein marker expression quantity, metabonomics and clinical data are obtained, the SNP effect values are corrected based on linkage imbalance reference information, and PRS is calculated in combination with the genotypes; constructing a protein expression score by utilizing the site effect value and the expression quantity of the pQTL, and fusing the protein expression score with the PRS to form a target PRS; carrying out dimensionality reduction on metabolome data by adopting sparse coding, extracting sparse coefficients of IPAH related metabolic pathways, and converting the sparse coefficients into metabolic pathway scores; converting the clinical indexes into clinical risk scores; based on the clinical parameter distribution target PRS, the metabolic pathway score and the weight coefficient of the clinical risk score, calculating a risk assessment value; and finally, matching the evaluation value with a preset risk threshold value, and outputting a risk evaluation level. And the IPAH risk assessment accuracy of common people is improved.

The invention relates to the technical field of biomedicine, in particular to a method for constructing a plasma ctDNA organ distribution characteristic spectrum of advanced colorectal cancer. The method comprises the following steps: collecting a peripheral blood sample at multiple time points, separating plasma by adopting a double-centrifugal method, and extracting circulating tumor DNA (Deoxyribose Nucleic Acid); carrying out whole exome sequencing based on ctDNA to obtain genome variation information and calculating variation allele frequency, and synchronously detecting the expression quantity of immune-related proteins by adopting an Olink proteomics technology; integrating the genome data, the protein expression data and the clinical pathological features, and constructing a multi-dimensional feature data matrix; and taking the organ metastasis condition confirmed by iconography as a supervision label, training a model by applying a machine learning algorithm, screening key prediction factors, constructing a quantitative prediction model, and finally generating a visual organ metastasis tendency prediction map. According to the method, early and accurate prediction of the advanced colorectal cancer organ metastasis tendency is realized through multi-omics data collaborative analysis and machine learning modeling.

The invention discloses a surface antigen gene StSAG1 of Sarcocystis tenella, the nucleotide sequence of the surface antigen gene StSAG1 is as shown in SEQ ID NO: 1, and according to the analysis result of protein antigenicity and antigen epitope, the 686 bp-1175 bp segment of the StSAG1 gene is selected to construct a recombinant protein expression vector and engineering bacteria; the antigen disclosed by the invention has very strong antigenicity and specificity, and can be subjected to effective antigen-antibody reaction with an antibody generated in serum after sheep (Ovis aries) is infected with sarcosporidium tenella, so that diagnosis is realized; low-titer antibodies can be detected two weeks after infection, and the detection window period is obviously advanced; by adopting the ELISA detection method, a visual result can be directly obtained. The method breaks through the limitation of an infection window period, has the advantages of low cost, high sensitivity, simplicity and convenience in operation, no need of expensive instruments and analysis and the like, is suitable for field detection in primary laboratories and pastures, and is beneficial to industrial production and market popularization and application.

The invention discloses a fungal effect protein prediction model based on a protein language model and deep learning, and relates to the technical field of bioinformatics and deep learning, and the method comprises the steps: 1, collecting fungal effect protein data and non-effect protein data; 2, obtaining protein embedding through a protein language model; 3, performing oversampling processing on the data; 4, constructing a deep learning model; 5, model training; and 6, performing cross validation and independent test evaluation. According to the invention, a geometric oversampling technology (G-SMOTE) is adopted to carry out oversampling processing, so that the problem of sample imbalance is solved; a protein language model is adopted to obtain protein embedding characteristics to strengthen protein expression; and the prediction accuracy is improved by using a deep learning model architecture. The method can be applied to agricultural disease prevention and control, drug development and biotechnology research, important support is provided for identification and research of fungal effect protein, prediction accuracy can be improved, dependence on expensive experiments is reduced, and labor cost is reduced.

The invention discloses application of sauchinone in cardiac fibrosis, relates to the technical field of medicines, and particularly relates to application of pharmaceutically acceptable salt derivatives of sauchinone in preparation of medicines for treating and / or relieving cardiac fibrosis. The sauchinone disclosed by the invention inhibits proliferation and migration of fibroblasts induced by Ang II. The sauchinone has a potential anti-cardiac fibrosis effect. The sauchinone can reduce the area of cardiac fibrosis and down-regulate mRNA level and protein expression of fibrosis related indexes, so that the sauchinone shows a potential anti-fibrosis effect.

The invention belongs to the technical field of biological medicine, and particularly relates to coriaria lactone compounds, a preparation method thereof and application of the coriaria lactone compounds in inhibition of alpha-SMA protein. The coriaria lactone compound can be used for remarkably inhibiting alpha-SMA protein expression of NRK-52E cells stimulated by TGF beta 1, and a basis is provided for developing high-selectivity anti-fibrosis drugs; the compound can be expanded to fibrosis treatment of multiple organs such as liver and lung, and has great clinical transformation value.

The invention discloses a nanoparticle for targeted protein degradation and a degradation method. The nanoparticles can enhance uptake of cells and effectively encapsulate specific antibodies for recognizing target proteins, and meanwhile, the interferon component can induce expression of TRIM family proteins in the cells. After ingestion into the cell, the antibody released by the nanoparticle can bind to the target protein and bind to the TRIM family protein to mediate degradation of the target protein. In this process, although the TRIM family protein is continuously consumed, the TRIM family protein can be compensated by the TRIM family protein expression induced by the particle of the invention, thereby maintaining efficient degradation.

The invention discloses a compound which is a compound as shown in a formula (I) or a stereoisomer, a tautomer, a solvate and a pharmaceutically acceptable salt of the compound as shown in the formula (I). As a liposome, the compound provided by the invention has high transfection efficiency, and especially can be used for delivering nucleic acid molecules (such as siRNA, mRNA and pDNA) to regulate expression of protein, or delivering CRISPR gene editing tools to realize knockout or repair of lesion genes.

The invention discloses an EmAGO2 truncated recombinant protein, an echinococcosis multilocularis indirect ELISA (enzyme-linked immuno sorbent assay) diagnostic kit based on the truncated recombinant protein and a use method of the kit. The method comprises the following steps: designing a specific primer by selecting a sequence of 1-738bp at the N end of an Em-AGO2 gene, carrying out PCR (Polymerase Chain Reaction) amplification by taking reverse transcription echinococcosis multilocularis DNA (Deoxyribonucleic Acid) as a template, connecting an amplification product with a pCE2-TA / Blunt vector, and then transforming into a competent cell for culturing, so as to obtain a pCE2-T-EmAGO2 plasmid; respectively carrying out double enzyme digestion on the plasmid and an expression vector pET-28a (+), and connecting enzyme digestion fragments to obtain a recombinant protein expression plasmid pET-28a-EmAGO2; the preparation method comprises the following steps: taking EmAGO2 as a template, transforming the EmAGO2 into competent cells, selecting positive clones for induced expression, and carrying out ultrasonication treatment, separation and purification, concentration and desalination treatment on expressed thalli to obtain the EmAGO2 truncated recombinant protein. Furthermore, a mouse anti-EmAGO2 truncated recombinant protein and goat anti-rabbit IgG are respectively used as an antigen and an antibody to establish an indirect ELISA diagnostic kit for the echinococcosis multilocularis, and the kit has high sensitivity, specificity and good repeatability, and can be used for early diagnosis of the echinococcosis multilocularis.

The invention relates to the technical field of nuclide probes, and discloses a targeted PARP nuclide probe and a preparation method and application thereof, and the targeted PARP nuclide probe comprises a radionuclide labeled compound as shown in formula I; the targeted PARP nuclide probe provided by the invention can be used as a diagnosis and treatment reagent to be applied to tumors with high PARP protein expression in human or animal bodies, and is especially suitable for tumor imaging and radionuclide treatment; animal experiments show that the nuclide probe has a high tumor / muscle uptake ratio and shows good application potential. Formula I.

The invention provides a multi-stream fusion gene sequence prediction method based on Mama and a double-coding strategy, and aims to improve semantic understanding and modeling capability of DNA sequences, so as to improve accuracy and generalization performance of protein expression value prediction. The method comprises the following steps: synchronously processing a forward chain and a reverse complementary chain of a DNA sequence: carrying out word segmentation and vectorization on the reverse complementary chain by adopting BPE coding to capture a semantic fragment; and the forward chain is subjected to one-hot coding and is linearly mapped into dense representation. Deep features of the two features are extracted through Mama Block and then are spliced and fused, then LSTM is input to model context dependence, and finally an expression value is output through a full connection layer. According to the method, the problems that biological semantic fragments are difficult to capture by One-Hot coding and functional domains are likely to be split by BPE coding are effectively solved. On the basis of a Mama framework, a local structure and global semantics are effectively combined, and the method is good at capturing long-distance dependence while low calculation complexity is kept, and is suitable for tasks such as gene design and protein expression regulation and control.

A method for characterizing disease activity in a systemic lupus erythematosus patient (SLE), comprising obtaining a dataset associated with a blood, serum, plasma or urine sample from the patient, assessing the dataset for a presence or an amount of protein expression of at least one innate serum or plasma mediator, assessing the dataset for a presence or an amount of protein expression of at least one adaptive serum or plasma mediator biomarker, assessing the dataset for a presence or an amount of at least one chemokine / adhesion molecule biomarker, assessing the dataset for a presence or an amount of at least one soluble TNF superfamily biomarker, assessing the dataset for a presence or an amount of at least one inflammatory mediator biomarker, assessing the dataset for a presence or an amount at least one SLE-associated autoantibody specificity biomarker and calculating a Lupus Disease Activity Immune Index (LDAII) score.

The invention belongs to the technical field of biological pharmacy, and provides an application of jonquil glucoside in preparation of a medicine for treating a metabolism-related fatty liver disease, and the application is that the jonquil glucoside is applied to preparation of the medicine for treating the metabolism-related fatty liver disease. The treatment effect of the jonquil glycoside on MASLD is evaluated by adopting a method for establishing a fatty liver model through induction of HFD high-fat, high-fructose and high-cholesterol feed. Results show that the jonquil glucoside can reduce the liver weight by inhibiting weight gain, reduce the content of TC and TG in serum, improve the conditions of liver inflammation and fat change, reduce the oxidative stress level of liver tissue and restore SIRT1 protein expression of the liver tissue to achieve the purpose of treating MASLD.

The invention discloses a plant lactobacillus and application thereof in preparation of gamma-aminobutyric acid and improvement of sleep, and relates to the technical field of biology. According to the present invention, the plant lactobacillus XBMU-SN-23 has been preserved in the China General Microbiological Culture Collection Center (CGMCC) on December 19, 2025, and the preservation number is CGMCC No.37118. The present invention further provides applications of the plant lactobacillus XBMU-SN-23 in gamma-aminobutyric acid preparation and sleep improvement. A metabolite of the strain XBMU-SN-23 has a sleep aiding function, and can regulate and control a neurotransmitter system to improve sleep quality by up-regulating GABA, 5-HT, IL-1 and MT, down-regulating Glu and DA and regulating protein quantity expression of a 5-HT1A receptor, a GABAAR alpha 1 receptor and a GABAAR gamma 2 receptor. Therefore, the plant lactobacillus XBMU-SN-23 has a wide application prospect in the product for preventing or treating insomnia.

The invention discloses a gastric cancer biomarker composition as well as a screening method and application thereof, and belongs to the technical field of bioinformatics. The screening method of the gastric cancer biomarker composition comprises the following steps: firstly, collecting blood specimens of a gastric cancer patient and a healthy control, carrying out high-throughput plasma proteomics detection, and screening out differential expression proteins; and verifying the candidate protein markers by using a prospective queue in the British biological sample library, and finally determining 17 core proteins to obtain the gastric cancer biomarker composition. A gastric cancer risk prediction model is constructed by combining clinical risk factors and protein expression levels of gastric cancer biomarkers. The gastric cancer risk prediction model constructed by the invention can realize accurate layering of gastric cancer risks, decision curve analysis shows that the net benefit of the model is obviously superior to that of a traditional screening method, and an efficient tool is provided for early warning and personalized intervention of gastric cancer.

The application discloses a microbial electrochemical system device and method for realizing wastewater treatment, CO2 fixation and in-situ synthesis of microbial protein synchronously, which comprises an anode chamber, a cathode chamber, a protein production chamber, a power supply, a mixed gas tank and a peristaltic pump; the anode chamber, the cathode chamber and the protein production chamber are sequentially arranged from left to right; a cation exchange membrane is arranged between the anode chamber and the cathode chamber; a cation exchange membrane is also arranged between the cathode chamber and the protein production chamber; an anode is arranged in the anode chamber and connected with the positive pole of the power supply through a wire, and a resistor is arranged on the wire connecting the anode and the positive pole of the power supply. The microbial electrochemical system and the protein production system are coupled to form an ammonia-nitrogen recovery-in-situ protein synthesis microbial electrochemical system, the system can convert active nitrogen into high-value protein products in-situ, the system can synchronously treat wastewater, recover ammonia-nitrogen and fix carbon dioxide, and has excellent environmental benefits.

The invention discloses a method for rapidly establishing an ovarian cancer model based on SauriCas9, and particularly discloses a recombinant plasmid for targeted knockout of Pten and Trp53 genes, and the recombinant plasmid comprises an EPI vector system. The recombinant plasmid takes an ori element as a replication start site, and sequentially comprises an sgRNA sequence of a targeted Trp53 gene and Pten controlled by double U6 promoters, a CAG promoter, a SauriCas9 nuclease expression unit, a fluorescent protein expression element, a resistance gene, an orip element and an EBNA1 protein expression element. The invention also discloses a method for rapidly establishing an ovarian cancer model based on SauriCas9, and the established ovarian cancer cell model. By adopting the method to construct the ovarian cancer cell model, the period from cell editing to animal tumor formation is shortened, the stability and immune integrity of the genetic background of the model are ensured, and large-scale drug screening and high-throughput experiments are facilitated.

Several embodiments relate to methods of repairing and / or regenerating damaged or diseased tissue comprising administering to the damaged or diseased tissues compositions comprising exosomes. In several embodiments, the exosomes comprise one or more microRNA that result in alterations in gene or protein expression, which in turn result in improved cell or tissue viability and / or function.

The invention provides an application of a super enhancer inhibitor JQ-1 in preparation of peripheral artery disease related drugs, relates to the technical field of biomedicine, and discloses a core effect of the super enhancer inhibitor JQ-1 in peripheral artery disease ischemia repair. The traditional Chinese medicine composition can significantly accelerate blood flow recovery of ischemic limbs, up-regulate mRNA and protein expression of a vascular marker CD31 in gastrocnemius muscle tissues, effectively increase vascular density and promote angiogenesis. Aiming at the defects of the existing treatment means in the aspect of ischemic tissue angiogenesis, the application provides a brand new molecular targeted treatment scheme for high-risk groups such as patients with diabetes-related peripheral artery diseases, and can significantly reduce the risk of lower limb amputation and the incidence rate of related cardiovascular adverse events such as coronary heart disease and stroke; the technical blank of specific targeted therapy of peripheral artery diseases is filled, a solid scientific basis and a key direction are provided for research and development of novel drugs, and the specific targeted therapy method has extremely high clinical application value and wide research and development prospects.

The invention discloses radix tetrastigme flavone synthase and application thereof. The radix tetrastigme flavone synthase comprises an amino acid sequence as shown in SEQ ID No. 2. The key enzyme-flavone synthase gene (ThFNS) related to synthesis of apigenin in radix tetrastigme is cloned for the first time, in-vitro recombinant protein expression and enzymatic reaction system verification show that flavone synthase can catalyze naringenin to generate apigenin, and technical support is provided for follow-up metabolic engineering modification for an apigenin biosynthetic pathway.

The invention relates to a response type DNA tetrahedral lysosome targeting chimera as well as a construction method and application thereof, and belongs to the technical field of biology. The response type DNA tetrahedron lysosome targeting chimera is obtained by self-assembling a tetrahedron I and a tetrahedron II; a sticky tail end H1 is arranged on the tetrahedron I, and a sticky tail end H2 is arranged on the tetrahedron II; three tyrosine kinase receptor aptamers are anchored on the first tetrahedron, three lysosome shuttle receptor aptamers are anchored on the second tetrahedron, stimuli-responsive factor aptamers are hybridized on the cohesive end H2, and the binding capacity with cells is obviously enhanced based on a trivalent aptamer modification strategy of a tetrahedral framework. According to the present invention, the VEGF is adopted as the stimulation response factor to construct the responsive DNA tetrahedral lysosome targeting chimera, and the responsive DNA tetrahedral lysosome targeting chimera carries the HER2 protein to the lysosome under the mediation of the lysosome shuttle receptor IGF2R so as to degrade, such that the HER2 protein expression on the cell membrane is reduced, and the degradation specificity and the degradation effect are enhanced.

The invention discloses application of lycium barbarum polysaccharide in preparation of a medicine for inhibiting methylamphetamine-induced nerve injury, and relates to the technical field of biological medicines. It is found and proved that lycium barbarum polysaccharide can inhibit methylamphetamine-induced nerve injury, and the effect is remarkable. From the aspect of cell survival, the survival rate of the microglial cells pretreated by the lycium barbarum polysaccharide after METH stimulation is obviously improved. In the molecular mechanism, the lycium barbarum polysaccharide can effectively lower the protein expression level of the METH-induced pyroptosis marker, the content of inflammatory factors IL-1beta and IL-18 can be reduced, and the release of lactic dehydrogenase is reduced. The result shows that the lycium barbarum polysaccharide can alleviate inflammatory response by inhibiting NLRP3 / ASC pathway mediated microglial cell pyroptosis, thereby inhibiting METH-induced nerve injury. The invention provides a new direction for developing METH neurotoxicity intervention medicines.